Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 65
Healthy Volunteers: f
View:
• Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
• Adult Patients aging from 20 to 65 years old
Locations
Other Locations
Egypt
Sherief Abd-Elsalam
RECRUITING
Tanta
Contact Information
Primary
Sherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com
00201147773440
Backup
sherief abd-elsalam, ass. prof.
sherif_tropical@yahoo.com
00201147773440
Time Frame
Start Date: 2018-11-01
Estimated Completion Date: 2028-12
Participants
Target number of participants: 60
Treatments
Active_comparator: Rifaximin
550 mg Rifaximin tablets twice daily for six months.
Experimental: Nitazoxanide
500 mg Nitazoxanide tablets twice daily for six months.
Related Therapeutic Areas
Sponsors
Leads: Tanta University